Ascletis’ Exciting Phase IB Results: Asc47 Monotherapy Shines in Australia and US, FDA Green-Lights Combination with Semaglutide
ASC47: A New Hope for Obesity Treatment with Long-Lasting Effects ASC47, a promising new drug candidate for the treatment of obesity, has recently grabbed the attention of researchers and health professionals with its impressive results in Phase Ib clinical trials. This adipose-targeted muscle-preserving weight loss drug has shown promising signs of effectiveness and safety in…